Skip to content

Allen & Overy advises Exscientia on its oncology joint venture with GT Apeiron Therapeutics

Related people
Ford Jim
Jim Ford

Partner

London

View profile →

Megan McMellon

Associate

London

View profile →

Press contacts

For media enquiries relating to this topic, please contact:

Image of Ben Davies, Senior Media Relations Manager
Ben Davies

Senior Media Relations Manager

London

View profile →

22 July 2021

Allen & Overy has advised Exscientia on its strategic research and development collaboration agreement with GT Apeiron Therapeutics (GTA). The collaboration will leverage Exscientia’s AI-driven drug discovery platform to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies.

Expanding on an existing CDK7 drug discovery partnership, the collaboration includes additional CDK targeting drugs. The potent, highly selective, non-covalent CDK7 compounds have demonstrated consistent tumour responses in xenograft models as well as exceptional pharmacokinetics. In addition, using live primary tissue samples from ovarian cancer patients, the CDK7 inhibitors showed both enhanced tumour cell cytotoxicity as well as selectivity over immune cells in the same microenvironment.

All pipeline products will be equally owned and Exscientia holds an equity stake in GTA.

The A&O team was led by London partner Jim Ford, assisted by London associate Megan McMellon.